文献速递咽喉与嗓音

单侧喉镜所见与慢性咳嗽患者加巴喷丁疗效的关联

Unilateral Laryngoscopic Findings Associated With Response to Gabapentin in Patients With Chronic Cough.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2017-01-01

这项回顾性队列研究纳入25例慢性咳嗽患者,评估喉镜下的声带运动不对称(VFMA)与加巴喷丁治疗反应的关系。结果显示,16例(64%)患者对加巴喷丁有部分或完全反应,其中94%的应答者存在VFMA,而无应答者中为56%,差异为38%(95%CI 18%-58%)。

要点

  • 慢性咳嗽患者中,声带运动不对称(VFMA)与加巴喷丁治疗反应相关。
  • 加巴喷丁应答者中VFMA比例(94%)高于无应答者(56%),差异38%。
  • 不良反应限制剂量在无应答者中更常见(44% vs 25%),但置信区间宽。

核心结论

  • 在疑似迷走神经病变相关的慢性咳嗽患者中,视频频闪喉镜下存在VFMA时,对加巴喷丁治疗应答的 odds 更高。

研究设计与样本

  • 回顾性队列研究,纳入2013年1月1日至2015年9月1日期间就诊于学术三级喉科门诊的慢性咳嗽(>8周)患者,共27例接受加巴喷丁处方,最终25例有随访数据。

主要发现

  • 25例患者中,女性15例(60%),平均年龄57岁(SD 11.8)。
  • 16例(64%)患者对加巴喷丁有部分或完全反应。
  • 20例(80%)患者存在声带运动不对称(VFMA)。
  • 应答者中15/16(94%)存在VFMA,无应答者中5/9(56%)存在VFMA,差异为38%(95%CI 18%-58%)。
  • 不良反应限制加巴喷丁剂量在无应答者中4/9(44%),应答者中4/16(25%),OR 2.5(95%CI 0.42-13.6)。

关键数值与推荐

  • 加巴喷丁起始剂量为100 mg每日两次,根据反应或不良反应滴定,最大日剂量为1800 mg。
  • 治疗反应定义为医生记录的患者主观咳嗽症状改善。

临床怎么用

  • 对于慢性咳嗽疑似迷走神经病变的患者,视频频闪喉镜下发现VFMA可能提示对加巴喷丁治疗更易应答。
  • 加巴喷丁治疗需注意不良反应,部分患者因不良反应限制剂量。

局限性

  • 回顾性研究,样本量小(25例),可能存在选择偏倚。
  • 治疗反应基于患者主观报告,缺乏客观指标。
  • 单中心研究,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Chronic cough is a debilitating, often multifactorial problem. Vagal neuropathy has been proposed as a cause for a fraction of these cases. There are certain features that support the clinical diagnosis of vagal neuropathy. It is hypothesized that patients with neurogenic cough who have vocal fold motion asymmetry (VFMA) on laryngoscopy will be more likely to respond to gabapentin. OBJECTIVE: To evaluate the association between the history, physical and videostroboscopic examinations, and clinical response to gabapentin. DESIGN, SETTING, AND PARTICIPANTS: In a retrospective cohort study, patients with chronic cough visiting an academic tertiary laryngology clinic from January 1, 2013, to September 1, 2015, were identified through International Classification of Diseases, Ninth Revision. Of those who had a chronic cough (>8 weeks), 27 patients who received a prescription for gabapentin were included. Patients without videostroboscopy, who did not complete voice therapy, or those without a follow-up examination more than 1 month from the initial evaluation were excluded. Initial history, physical and videostroboscopic examinations, and follow-up evaluations, were performed in a multidisciplinary laryngology clinic including a speech-language pathologist. Documented VFMA by a multidisciplinary team was decided by consensus after review of videostroboscopy recording at the time of the visit. MAIN OUTCOMES AND MEASURES: Response to gabapentin was defined by physician-documented subjective patient report of improvement in cough symptoms. RESULTS: Follow-up data were available on 25 of the 27 patients (15 [60%] women; mean [SD] age, 57 [11.8] years). Therapy was initiated in patients with chronic cough with gabapentin, 100 mg twice daily, which was titrated to response or adverse effects. The maximum daily dose was 1800 mg. Partial or complete response to gabapentin was noted in 16 (64%) patients. Vocal fold motion asymmetry was noted in 20 (80%) patients. Fifteen of 16 (94%) responders had VFMA compared with 5 of 9 (56%) nonresponders. The difference in the frequency of VFMA between responders and nonresponders was 38% (95% CI, 18%-58%). Adverse effects limited the gabapentin dose in 4 of 9 (44%) nonresponders and 4 of 16 (25%) responders (odds ratio, 2.5; 95% CI, 0.42-13.6). CONCLUSIONS AND RELEVANCE: In patients with chronic cough suspected to be related to vagal neuropathy, the odds of response to gabapentin are higher with the presence of VFMA noted on videostroboscopy.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Giliberto JP, Dibildox D, Merati A, et al. Unilateral Laryngoscopic Findings Associated With Response to Gabapentin in Patients With Chronic Cough. JAMA Otolaryngol Head Neck Surg. 2017. PMID: 28910442. doi:10.1001/jamaoto.2017.1557

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。